[Surgical solution to vitreous floaters visual problem].
OBJECTIVE
To evaluate the role of 25 gauge pars-plana vitrectomy (25G-PPV), after a careful patient selection, when we find highly annoying vitreous floaters and to question if this is an ethical therapeutic option.


METHODS
A retrospective study of eight eyes (seven patients) aged 58+/-14 years old (range 42-78) high myopes and pseudophakes who underwent 25G-PPV. Clinical data and visual acuity were studied at six to twelve months follow-up. Health-related functioning and quality of life was measured with the 39-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-39).


RESULTS
No complications were observed. All patients were satisfied. Safety at third month was 100% and 37.5% improved one or more lines of visual acuity.


CONCLUSIONS
Vitreous floaters can be often undervaluated by ophthalmologists, resulting in no intervention. Conventional 20 gauge PPV after a carefully examination can be an effective option for some authors. 25G-PPV incorporates also advantages as the early recovery, with little complications in pseudophakic eyes.
Martínez-Sanz
F
F
Instituto Cántabro de Oftalmología, Santander, Spain. oftmsf@humv.es
Velarde
J I
JI
Casuso
P
P
Fernández-Cotero
J N
JN
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D005128:Eye Diseases / Q000523:psychology / Q000601:surgery*; D005260:Female; D006801:Humans; D017075:Laser Coagulation; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000150:complications / Q000188:drug therapy; D015814:Ocular Hypotension / Q000150:complications / Q000188:drug therapy; D017060:Patient Satisfaction; D019591:Pseudophakia / Q000150:complications; D011788:Quality of Life; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014821:Vitrectomy / Q000941:ethics / Q000379:methods / Q000523:psychology; D014822:Vitreous Body / Q000601:surgery*
D000305:Adrenal Cortex Hormones; D000319:Adrenergic beta-Antagonists